NEWS
Our Latest News
ARCHIMED concludes successfully its £203 million take-private bid for drug development software leader Instem
ARCHIMED’s NAMSA announces key acquisition of Syntactx
January
5,
2021
ARCHIMED gives several million euros to the EURÊKA Foundation its philanthropic arm
November
25,
2020
Partnering with existing owners and management, ARCHIMED acquires majority interest in NAMSA, the world leader in medical device testing
September
1,
2020
ARCHIMED raises €1 billion for its MED Platform I Fund
August
28,
2020
368